drugset
drugset / Trial / NCT01471704

Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers

NCT01471704 ↗

Phase 1/2 Completed 24 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelHealth-services research

Summary

The purpose of this study is to evaluate the potential for a pharmacokinetic (PK) drug-drug interaction between INX-08189 and extended release verapamil hydrochloride (verapamil HCL ER).

Timeline

Start
2011-10
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986094 Small molecule 50 mg —
Comparator Verapamil Other / unclassified 240 mg —

Indications

No indication recorded.